Citadel Advisors
MNPR icon

Citadel Advisors’s Monopar Therapeutics MNPR Stock Holding History

Citadel Advisors’s Portfolio MNPR Stock Details MNPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.43M Sell
37,004
-21,432
-37% -$1.33M ﹤0.01% 5423
2026
Q1 		$3.2M Buy
58,436
+53,363
+1,052% +$3.22M ﹤0.01% 5134
2025
Q4 		$331K Buy
+5,073
New +$414K ﹤0.01% 9924
2025
Q3 		– Sell
-6,232
Closed -$223K – 13602
2025
Q2 		$223K Buy
+6,232
New +$226K ﹤0.01% 10455
2021
Q2 		– Sell
-2,496
Closed -$77K – 14112
2021
Q1 		$77K Buy
+2,496
New +$91.1K ﹤0.01% 12666

Other funds holding MNPR

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Citadel Advisors's MNPR Position: Q2 2026 in Review

Citadel Advisors reduced its Monopar Therapeutics (MNPR) stake by 37% in Q2 2026, selling an estimated $1.33M and leaving 37,004 shares worth $3.43M. The position accounts for ﹤0.01% of the portfolio, ranked #5423.

Citadel Advisors first reported a position in MNPR in Q1 2021 and has held it in 5 quarters since. 96 funds tracked by Wall St. Rank hold MNPR as of Q2 2026.

  • Citadel Advisors held 37,004 shares of Monopar Therapeutics worth $3.43M as of Q2 2026.
  • Citadel Advisors sold 21,432 Monopar Therapeutics shares in Q2 2026, an estimated $1.33M.
  • Monopar Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #5423 holding.
  • Citadel Advisors first reported a position in Monopar Therapeutics in Q1 2021 and has held it in 5 quarters since.
  • 96 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.